LSLeila Saadatpour

Leila Saadatpour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leila Saadatpour has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Pilot Randomized Trial of Physical Therapy with Atomoxetine or Methylphenidate for Gait and Balance Impairment in Parkinson’s Disease (The TAME-PD Study)

    by Saar Anis, Xiomara Garcia, Xin Xin Yu, Tanaporn Rasameesoraj, Diana Hengartner, Shnehal Patel, Adam Margolius, James Liao, Leila Saadatpour, Camila Callegari Piccinin, et al.

    Background: Gait impairment in Parkinson's disease (PD) responds poorly to dopaminergic therapy. Whether catecholaminergic augmentation of physical therapy (PT) improves outcomes has not been tested in randomized trials.Objective: To assess feasibility and preliminary effects of adding atomoxetine or methylphenidate to structured PT in PD.Methods: TAME-PD was a single-center, randomized, rater-blinded pilot trial. Participants were randomized to PT alone, PT + atomoxetine 10 mg/day, or PT + methylphenidate 20 mg/day for 12 weeks. The primary outcome was change in Mini-Balance Evaluation Systems Test (Mini-BESTest) score at week 12.Results: Of 23 randomized participants, 18 had complete baseline and week-12 Mini-BESTest data. The primary outcome did not differ significantly between groups (Kruskal-Wallis p=0.099). Nonetheless, median improvement was 4.0 points with atomoxetine + PT, 2.0 with PT alone, and 1.5 with methylphenidate + PT. The effect-size point estimate for atomoxetine + PT versus PT alone was large (Cliff's δ=0.54, 95% CI −0.08 to 0.86); 80% of atomoxetine participants achieved the 4-point minimal clinically important difference versus 29% with PT alone and 17% with methylphenidate + PT. In the mixed-effects model, atomoxetine + PT improved more than methylphenidate + PT (+2.26 points; p=0.033; Holm-adjusted p=0.26); neither medication differed significantly from PT alone. Pooled medication-arm analysis showed no advantage over PT alone (p=0.68).Conclusions: Although this under-enrolled pilot trial was not conclusive, participants who received atomoxetine + PT showed greater median improvement in balance. These preliminary findings support further study of atomoxetine as a PT adjunct in PD with gait instability.

  • Open Access

    A Pilot Randomized Trial of Physical Therapy with Atomoxetine or Methylphenidate for Gait and Balance Impairment in Parkinson’s Disease (The TAME-PD Study)

    by Saar Anis, Xiomara Garcia, Xin Xin Yu, Tanaporn Rasameesoraj, Diana Hengartner, Shnehal Patel, Adam Margolius, James Liao, Leila Saadatpour, Camila Callegari Piccinin, et al.

    Background: Gait impairment in Parkinson's disease (PD) responds poorly to dopaminergic therapy. Whether noradrenergic augmentation of physical therapy (PT) improves outcomes has not been tested in a randomized trial.Objective: To evaluate the feasibility and preliminary efficacy of adding atomoxetine or methylphenidate to structured PT in PD.Methods: TAME-PD was a single-center, randomized, rater-blinded pilot trial. Participants with PD and gait impairment were randomized to PT alone, PT + atomoxetine 10 mg/day, or PT + methylphenidate 20 mg/day for 12 weeks. The primary outcome was the change in Mini-Balance Evaluation Systems Test (Mini-BESTest) score at week 12. Analyses included Kruskal-Wallis tests, Cliff's delta, responder analysis, and linear mixed-effects models.Results: Of 23 randomized participants, 18 had complete baseline and week-12 Mini-BESTest data. Median Mini-BESTest improvement was 4.0 with atomoxetine + PT, 1.5 with methylphenidate + PT, and 2.0 with PT alone (p=0.099). The PT + atomoxetine-versus-PT alone effect size was large (Cliff's δ=0.54), and 80% of atomoxetine-medicated participants achieved the 4-point clinically important difference versus 29% with PT alone and 17% with PT + methylphenidate. In the longitudinal model, atomoxetine showed greater improvement than methylphenidate (+2.26 points; p=0.033; adjusted p=0.26 after Holm correction), whereas neither medication differed significantly from PT alone. The pooled medication-arm analysis showed no advantage over PT alone (+0.38 points; p=0.68).Conclusions: Although this under-enrolled pilot trial was not conclusive, participants who received atomoxetine with PT tended to improve balance. These preliminary findings support further study of atomoxetine as a PT adjunct in PD with gait instability.

  • Open Access

    DAT and TH expression marks human Parkinson’s disease in peripheral immune cells

    by Adithya Gopinath, Phillip Mackie, Basil Hashimi, Anna Marie Buchanan, Aidan R. Smith, Rachel Bouchard, Gerry Shaw, Martin Badov, Leila Saadatpour, Aryn Gittis, et al.

    Parkinson’s disease (PD) is marked by a loss of dopamine neurons, decreased dopamine transporter (DAT) and tyrosine hydroxylase (TH) expression. However, this validation approach cannot be used for diagnostic, drug effectiveness or investigational purposes in human patients because midbrain tissue is accessible postmortem. PD pathology affects both the central nervous and peripheral immune systems. Therefore, we immunophenotyped blood samples of PD patients for the presence of myeloid derived suppressor cells (MDSCs) and discovered that DAT+/TH+monocytic MDSCs, but not granulocytic MDSCs are increased, suggesting a targeted immune response to PD. Because in peripheral immune cells DAT activity underlies an immune suppressive mechanism, we investigated whether expression levels of DAT and TH in the peripheral immune cells marks PD. We found drug naïve PD patients exhibit differential DAT+/TH+expression in peripheral blood mononuclear cells (PBMCs) compared to aged/sex matched healthy subjects. While total PBMCs are not different between the groups, the percentage of DAT+/TH+PBMCs was significantly higher in drug naïve PD patients compared to healthy controls irrespective of age, gender, disease duration, disease severity or treatment type. Importantly, treatment for PD negatively modulates DAT+/TH+expressing PBMCs. Neither total nor the percentage of DAT+/TH+PBMCs were altered in the Alzheimer’s disease cohort. The mechanistic underpinning of this discovery in human PD was revealed when these findings were recapitulated in animal models of PD. The reverse translational experimental strategy revealed that alterations in dopaminergic markers in peripheral immune cells are due to the disease associated changes in the CNS. Our study demonstrates that the dopaminergic machinery on peripheral immune cells displays an association with human PD, with exciting implications in facilitating diagnosis and investigation of human PD pathophysiology.


  • Mixed Transcortical Aphasia in Association with Neurodegenerative Disease (P6.080)

    by Usama Tariq, Alicia Parker, Leila Saadatpour, Fareed Khan, Hoss Mardani, Doty Leilani, Kenneth Heilman